| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 763.7 | 769.0 |
| Profit before tax | 183.3 | 144.0 |
| Net income | 141.2 | 119.0 |
| EPS (diluted, $ a share) | $1.04 | $0.88 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +18.7% |
|---|---|
| Revenue, year on year | -0.7% |
| Operating margin | 23.2% |
10-Q filed with the SEC, NYSE: GMED. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Globus Medical Inc: key numbers
- Share price
- $70.50Close, Nov 16
- Market cap
- $9.47B
- Shares outstanding
- 134.26MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Globus Medical Inc
All →Globus Medical Director James R. Tobin Sells $3.13M of Stock
James R. Tobin, Director, sold 41,666 shares of Globus Medical Inc at $75.10 to $75.68 a share (average $75.16) in 2 transactions, worth $3.13M in total on Nov 10, 2026. Shares held after the trade: 0 (-100.0%).
- Value
- $3.13M
- Shares
- 41,666
- Average price
- $75.16
- Role
- Director
- Holding change
- -100.0%
- Trade date
- Nov 10, 2026
Globus Medical Director Ann D. Rhoads Sells $425K of Stock
Ann D. Rhoads, Director, sold 5,000 shares of Globus Medical Inc at $85.00 a share, worth $425K in total on Nov 4, 2026. Shares held after the trade: 35,384 (-12.4%).
- Value
- $425K
- Shares
- 5,000
- Price
- $85.00
- Role
- Director
- Holding change
- -12.4%
- Trade date
- Nov 4, 2026
Globus Medical Financial Results
Globus Medical reported Q3 2026 financial results with net sales of $763.7 million and GAAP net income of $141.2 million. Simultaneously, the company announced that its Board of Directors authorized a $500 million increase to its existing share repurchase program, bringing the total available for future buybacks to approximately $611 million.
“Third quarter revenue finished at $764 million, down slightly from the prior year quarter. U.S. Spine faced difficult prior year comparables, growing 2% in the third quarter, as compared to double digit growth in the prior year quarter. On an average two-year basis, the U.S. Spine business is growing mid-single digits, reflecting our ability to capture share in the market, as we lead with innovation and differentiation.”
Keith Pfeil, President and Chief Executive Officer
“Our third quarter results highlight our Company’s commitment to delivering consistent adjusted gross profit margin expansion, bottom-line profit, and free cash flow generation, as we delivered the eighth straight quarter of sequential adjusted gross profit margin expansion and record quarterly operating cash flow and free cash flow generation.”
Kyle Kline, Chief Financial Officer
Globus Medical Director James R. Tobin Sells $2.24M of Stock
James R. Tobin, Director, sold 30,000 shares of Globus Medical Inc at $74.58 a share, worth $2.24M in total on Sep 15, 2026. Shares held after the trade: 0 (-100.0%).
- Value
- $2.24M
- Shares
- 30,000
- Price
- $74.58
- Role
- Director
- Holding change
- -100.0%
- Trade date
- Sep 15, 2026